Board of Directors
Jaymin Amin
CEO
Mr. Jaymin Amin, B.Eng., has a successful track record of 20 years of sales, marketing and financial experience in life science start-ups.
In September 2011 Jaymin was appointed to the Board of Directors of ProfactorPharma as a non-executive director. And in August 2016 Jaymin was named, and is currently serving as the Chief Executive Officer.
Dr. Malcolm Weir
Non-Executive Chairman
Malcolm is a successful biotech scientist and entrepreneur. He was the Head of Biomolecular Structure and the Molecular Sciences Division of GlaxoWellcome with responsibility in target validation and lead discovery, CEO of structural bioinformatics and drug discovery company Inpharmatica Ltd, sold to Galapagos in 2006, before co-founding Heptares Therapeutics Ltd in July 2007, pioneering Structure-based Drug Design of G Protein-coupled receptors and creating a pipeline of >10 GPCR NCEs in the clinic to date. Heptares was sold to Sosei (Now NXera) in 2015 for up to $400M. Malcolm is also a haemophilia A patient and strong advocate for access to treatment to all haemophilia patients worldwide.
Eugenia Wachters
COO
Eugenia brings 30 years of experience in Commercial Operations and General Management in the Pharma/Biotech world. She has worked for several top pharmaceutical companies (GSK, Boehringer Ingelheim and Sanofi), driving the launch and commercialization of several global brands. She has worked as VP Commercial Operations for Emerging markets at Sanofi, working closely with local teams across the region to optimize the commercial performance and was General Manager for Sanofi UK (General Medicines). In 2020, she moved to Healx, where she worked as VP Commercial and Operations, developing the commercial portfolio strategy and setting up program management, before joining PFP in July 2023.
Professor John H McVey PhD, FRCPath
Co-Founder, CSO
Professor McVey PhD, FRCPath has more than 20 years experience in blood coagulation factors (http://themcveylab.com/index.html) having worked with Ian Garner at Delta Biotechnology during his time at the MRC National Institute for Medical Research (Mill Hill) back in 1988/89. It was this encounter which would eventually lead to the creation of Profactor Pharma.
Dr. Ian Fotheringham
CTO/Director
Ian Fotheringham is the CEO at Ingenza Ltd and has been hugely supportive of the company since the business relationship started. He represents Ingenza’s interest in PFP as well as providing technical advice. He received a Ph.D. in Molecular Biology with Professor David Sherratt at the University of Glasgow in 1986. Joining the NutraSweet division of Monsanto Corporation in Chicago IL, he then spent 6 years developing microbial strains for the manufacture of L-phenylalanine and the peptide sweetener Aspartame.
Bruce Vernon
Co-Founder, Advisor Regulatory Affairs and QA, Founder
Bruce has a Master’s degree in Immunology and has more than 30 years experience in the development, manufacture and quality assurance and control of biological products including four years in the UK National Blood Transfusion Service and with the Nepalese Red Cross blood transfusion service. He was brought into the founding team of PFP to guide the all important regulatory aspects of biopharmaceutical product development.